| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6265 | 2012 |
| Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009 | 2949 | 2009 |
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells MA Molina, J Codony-Servat, J Albanell, F Rojo, J Arribas, J Baselga Cancer research 61 (12), 4744-4749, 2001 | 1065 | 2001 |
| Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs MA Molina, M Sitja-Arnau, MG Lemoine, ML Frazier, FA Sinicrope Cancer research 59 (17), 4356-4362, 1999 | 550 | 1999 |
| Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations R Rosell, MA Molina, C Costa, S Simonetti, A Gimenez-Capitan, ... Clinical Cancer Research 17 (5), 1160-1168, 2011 | 357 | 2011 |
| Mechanism of action of trastuzumab and scientific update J Baselga, J Albanell, MA Molina, J Arribas Seminars in oncology 28, 4-11, 2001 | 354 | 2001 |
| NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer MA Molina, R Sáez, EE Ramsey, MJ Garcia-Barchino, F Rojo, AJ Evans, ... Clinical cancer research 8 (2), 347-353, 2002 | 307 | 2002 |
| The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in … C Costa, MA Molina, A Drozdowskyj, A Giménez-Capitán, ... Clinical cancer research 20 (7), 2001-2010, 2014 | 276 | 2014 |
| KRAS mutations in lung cancer N Karachaliou, C Mayo, C Costa, I Magrí, A Gimenez-Capitan, ... Clinical lung cancer 14 (3), 205-214, 2013 | 268 | 2013 |
| Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial N Karachaliou, C Mayo-de las Casas, C Queralt, I de Aguirre, B Melloni, ... JAMA oncology 1 (2), 149-157, 2015 | 266 | 2015 |
| p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer R Sáez, MA Molina, EE Ramsey, F Rojo, EJ Keenan, J Albanell, A Lluch, ... Clinical cancer research 12 (2), 424-431, 2006 | 258 | 2006 |
| Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, ... Therapeutic advances in medical oncology 10, 1758834017749748, 2018 | 251 | 2018 |
| PTEN and PI3K/AKT in non-small-cell lung cancer C Pérez-Ramírez, M Cañadas-Garre, MÁ Molina, MJ Faus-Dáder, ... Pharmacogenomics 16 (16), 1843-1862, 2015 | 228 | 2015 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 214 | 2017 |
| Real-time liquid biopsies become a reality in cancer treatment N Karachaliou, C Mayo-de-Las-Casas, MA Molina-Vila, R Rosell Annals of translational medicine 3 (3), 2015 | 177 | 2015 |
| Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC I Chaib, N Karachaliou, S Pilotto, J Codony Servat, X Cai, X Li, ... JNCI: Journal of the National Cancer Institute 109 (9), djx014, 2017 | 152 | 2017 |
| Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations I Garcia-Olivé, E Monsó, F Andreo, J Sanz-Santos, M Taron, ... European Respiratory Journal 35 (2), 391-395, 2010 | 152 | 2010 |
| Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non–small cell lung cancer MA Molina-Vila, J Bertran-Alamillo, A Gascó, C Mayo-de-las-Casas, ... Clinical Cancer Research 20 (17), 4647-4659, 2014 | 147 | 2014 |
| Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer K Jacobsen, J Bertran-Alamillo, MA Molina, C Teixidó, N Karachaliou, ... Nature communications 8 (1), 410, 2017 | 137 | 2017 |
| Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth C Blanco-Aparicio, MA Molina, E Fernández-Salas, ML Frazier, JM Mas, ... Journal of Biological Chemistry 273 (20), 12370-12377, 1998 | 136 | 1998 |
